The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease


Division of Nephrology and Hypertension, Departments of Medicine (W.L.L., N.D.V., A.C.F.N., M.K.) and Molecular Biology and Biochemistry (W.E., J.P., K.W.), University of California, Irvine, California; Centre for Comparative Genomics and Evolutionary Bioinformatics Integrated Microbiome Resource, Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada (A.M.C., M.G.I.L.); and Department of Cardiology, Fukuoka University, Fukuoka, Japan (Y.S.)

Received June 12, 2018; accepted September 28, 2018

ABSTRACT

In chronic kidney disease (CKD), the gut microbiome is altered and bacterial-derived uremic toxins promote systemic inflammation and cardiovascular disease. Ferric citrate complex is a dietary phosphate binder prescribed for patients with end-stage kidney disease to treat hyperphosphatemia and secondary hyperparathyroidism. Iron is an essential nutrient in both microbes and mammals. This study was undertaken to test the hypothesis that the large iron load administered with ferric citrate in CKD may significantly change the gut microbiome. Male Sprague-Dawley rats underwent 5/6 nephrectomy to induce CKD. Normal control and CKD rats were randomized to regular chow or a 4% ferric citrate diet for 6 weeks. Fecal and cecal microbial DNA was analyzed via 16S ribosomal RNA gene sequencing on the Illumina MiSeq system. CKD rats had lower abundances of Firmicutes and Lactobacillus compared with normal rats and had lower overall gut microbial diversity. CKD rats treated with ferric citrate had improved hemoglobin and creatinine clearance and amelioration of hyperphosphatemia and hypertension. Ferric citrate treatment increased bacterial diversity in CKD rats almost to levels observed in control rats. The tryptophanase-possessing families Verrucomicrobia, Clostridiales, and Enterobacteriaceae were increased by ferric citrate treatment. The uremic toxins indoxyl sulfate and p-cresyl sulfate were not increased with ferric citrate treatment. Verrucomicrobia was largely represented by Akkermansia muciniphila, which has important roles in mucin degradation and gut barrier integrity. In summary, ferric citrate therapy in CKD rats was associated with significant changes in the gut microbiome and beneficial kidney and blood pressure parameters.

Introduction

Systemic inflammation is invariably present in humans and animals with chronic kidney disease (CKD) and is marked by activation of circulating leukocytes and elevation of plasma proinflammatory cytokines and chemokines (Yoon et al., 2007; Kato et al., 2008; Heine et al., 2012). CKD-associated systemic inflammation and oxidative stress play a central role in the pathogenesis of numerous complications of CKD, including accelerated cardiovascular disease, frailty, and anemia, among others (Himmelfarb et al., 2002; Vaziri, 2004; Cachofeiro et al., 2008). There are profound changes in the structure and function of the gut microbiome and disruption of the gut epithelial barrier in CKD (Vaziri et al., 2012, 2013a,b). Increased permeability of the intestinal epithelium in CKD is evidenced by the appearance of orally administered high molecular weight polyethylene glycols in the urine (Magnusson et al., 1990, 1991). Several studies have demonstrated the role of gut microbial-derived uremic toxins such as indoxyl sulfate, p-cresyl sulfate, and trimethylamine N-oxide in the pathogenesis of CKD-associated systemic inflammation (Liabeuf et al., 2010; Aronov et al., 2011; Tang et al., 2015; Stubbs et al., 2016). Endotoxin, derived from the cell wall of Gram-negative bacteria, is measurable in the blood of patients with CKD and increases with severity of CKD stage, being most elevated in chronic dialysis patients (Szeto et al., 2008; McIntyre et al., 2011).

Several factors contribute to the gut microbial dysbiosis in patients with advanced CKD. First, accumulation of urea in the body fluids and its diffusion in the gastrointestinal tract leads to the expansion of urease-possessing bacteria (Wong et al., 2014). Hydrolysis of urea by these microbial species...
results in the formation of ammonia and caustic ammonium hydroxide \[\text{CO(NH}_2\text{)}_2 + \text{H}_2\text{O} \rightarrow \text{CO}_2 + 2\text{NH}_3; \text{NH}_3 + \text{H}_2\text{O} \rightarrow \text{NH}_4\text{OH}\], which degrade the epithelial tight junction (Vaziri et al., 2013c), thereby facilitating translocation of endotoxin and microbial fragments into the systemic circulation (Wang et al., 2012; Lau et al., 2015; Vaziri et al., 2016). Second, dietary restrictions to limit hyperkalemia and hyperphosphatemia in CKD correlate with a diet low in potassium-rich (fruits and vegetables) and phosphate-rich (cheese and yogurt) products. These dietary restrictions result in the unintended reduction of digestible complex carbohydrates, a nutrient source for gut microbial flora, from which they generate short-chain fatty acids. Short-chain fatty acids in turn are major nutrients for colonocytes and are essential for the integrity of the colonic epithelium. In addition, the reduction of short-chain fatty acid production and formation of ammonium hydroxide leads to a rise in the pH of the colonic milieu, which further impacts the gut microbial community (Sirich et al., 2014; Kieffer et al., 2016). Furthermore, the limited intake of cheese and yogurt reduces exposure to useful symbiotic bacteria. Third, pharmaceutical interventions including commonly prescribed phosphate or potassium binders significantly alter the biochemical milieu of the gut and can potentially impact the gut microbiome. However, to our knowledge, the effect of these compounds on the gut microbiome in CKD has not been previously investigated.

Ferric citrate is a calcium-free iron compound used as a dietary phosphorus binder to manage hyperphosphatemia in patients with end-stage kidney disease (Yokoyama et al., 2012, 2014; Lee et al., 2015; Lewis et al., 2015), administered in doses that provide 2–4 g elemental iron per day. Ferric citrate has been shown to ameliorate secondary hyperparathyroidism and vascular calcification in CKD (Iida et al., 2013; Block et al., 2015). Ferric citrate has additional benefits, in that it improves iron deficiency anemia by restoring iron stores. In a phase III randomized controlled trial of ferric citrate therapy in nondialysis patients with CKD, mean transferrin saturation and ferritin were increased by 18.4% and 170 ng/ml, respectively, after 16 weeks of therapy (Fishbane et al., 2017).

Iron is an essential nutrient in both microbes and mammals. Microbes acquire iron by producing siderophores, which are small molecules that chelate and internalize iron. Siderophores play a major role in microbial physiology and virulence, and they can modulate interbacterial competition and host cellular pathways (Holden and Bachman, 2015; Wilson et al., 2016). However, it is unknown whether gut microbes would be affected by ferric citrate therapy. Studies in non-CKD rodents have demonstrated varying effects of ferrous sulfate supplementation on the gut microbiome, including a decrease in the proportion of strict anaerobes (Benoni et al., 1993; Tompkins et al., 2001; Alexeev et al., 2017). Studies in CKD models to examine the impact of iron supplementation on the gut microbiome are lacking. Given the critical role of iron in microbial growth and virulence, this study was undertaken to test the hypothesis that the large iron load administered with ferric citrate in CKD may result in significant changes in the gut microbiome. To this end, the fecal microbiome was characterized in both normal and CKD rats treated with or without ferric citrate in their chow for 6 weeks.

Materials and Methods

Animals. All experiments were approved by the University of California, Irvine Institutional Committee for the Use and Care of Experimental Animals. Eight-week-old male Sprague-Dawley rats were purchased from Charles River Laboratories (Raleigh, NC). They were housed in a climate-controlled vivarium with 12-hour day/night cycles and were provided access to food and water ad libitum. The CKD groups were subjected to 5/6 nephrectomy by removing the upper and lower thirds of the decapsulated left kidney, followed by right nephrectomy 7 days later as described previously (Vaziri et al., 2007). The normal control group (NL) underwent a sham operation. General anesthesia was induced with 5% inhaled isoflurane (Piramal Critical Care, Bethlehem, PA) and maintained at 2%–4% isoflurane during surgery. For pain relief, rats were given 0.05 mg/kg Buprenex (Reckitt Beneciser Pharmaceutical Inc., Richmond, VA). The NL and CKD groups were randomly assigned to a regular diet or a diet containing 4% ferric citrate for 6 weeks (denoted as the NL+FC and CKD+FC groups, respectively). The animals were then placed in metabolic cages for a 24-hour urine collection. Systolic blood pressure was measured by tail plethysmography as described previously (Vaziri et al., 2002). Animals were euthanized by cardiac exsanguination under isoflurane anesthesia and colons were resected. Cecal and colon stool contents were collected and processed for determination of microbial community composition as described below.

Blood and Urine Biochemistries. Plasma phosphorus, calcium, iron, blood urea nitrogen, and urine creatinine were determined using Quantichrom Assay Kits from BioAssay Systems (Hayward, CA). Plasma creatinine was measured using capillary electrophoresis at the O’Brien Kidney Research Core Center (University of Texas Southwestern, Dallas, TX). Blood hemoglobin was determined using the AimStrip Hb meter (Ermarine Laboratories Inc., San Antonio, TX).

Mass Spectrometry for Indoxyl Sulfate and p-Cresyl Sulfate. Analysis was done at the Mass Spectrometry Facility at the University of California, Irvine Chemistry Department (Irvine, CA). We used a modified protocol based on previously described methods (Shu et al., 2016; Kanemitsu et al., 2017). A 0.1-ml aliquot of plasma was treated with 200 µl acetonitrile for protein precipitation containing 2 µg/ml hydroxylrothiazide. Hydrochlorothiazide was used as the internal standard. The mixture was vortexed and homogenized for 10 minutes in a water bath sonicator then centrifuged at 16,400g for 15 minutes at 4°C. The supernatant was collected, injected into a 2-ml microcentrifuge tube and evaporated to dryness at 60°C. The dried extract was reconstituted with 100 µl 25% acetonitrile. Indoxyl sulfate, p-cresyl sulfate, and hydrochlorothiazide reference standards were purchased from Fisher Scientific (cat. nos. 50115115, AAA1707091, and 5001437615; Rockford, IL). A stock 2 mg/ml solution was prepared with water and dilutions were prepared with 25% acetonitrile with 4 µg/ml hydrochlorothiazide (internal standard) to generate a standard curve ranging from 1 to 2000 ng/ml. Standards and prepared samples were injected (10 µl) into the high-performance liquid chromatography–tandem mass spectrometry instrument, a Waters Quattro Premier XE (Waters, Milford, MA) equipped with a ultra-performance liquid chromatography system. The ultra-performance liquid chromatography system has a BEH C18 column, which allows rapid sample throughput. Mobile phase A was water with 5 mM ammonium formate, and mobile phase B was 95% methanol with 5 mM ammonium formate. Analysis was performed in negative ionization mode by using multiple reaction monitoring tandem mass spectrometry with standard calibration. The transition \(m/z\) values were as follows: indoxyl sulfate, 211.97 > 80.36; p-cresyl sulfate, 186.94 > 107.30; and hydrochlorothiazide, 296.96 > 270.08.

Microbial DNA Extraction and 16S Ribosomal RNA Gene Amplicon Sequencing. Cecal and fecal samples stored at −80°C were sent to the Centre for Comparative Genomics and Evolutionary Bioinformatics Integrated Microbiome Resource at Dalhousie University (Halifax, NS, Canada) for extraction, library preparation, and

Downloaded from jpet.aspetjournals.org at ASPET Journals on July 6, 2021
sequencing of the 16S V6–V8 region on an Illumina MiSeq system (San Diego, CA). Microbial DNA was extracted with a Mo Bio PowerFecal extraction kit (QIAGEN, Germantown, MD), and amplification and sequencing was done as previously described (Comeau et al., 2017) (also see http://cgeb-imr.ca/protocols.html).

Sequence Analysis. A total of 32,000 sequences per sample were retained following quality control filtering and rarefaction, and these remaining sequences were clustered into 97% operational taxonomic units (OTUs) using open-reference clustering. All steps were conducted with Microbiome Helper, as described previously (Rossi et al., 2014). The resulting OTU table was then used for further analysis within the Vegan package in R software (R Foundation for Statistical Computing, Vienna, Austria) (Oksanen et al., 2007). α- and β-diversity metrics were calculated, and data were also analyzed using the STAMP software package (Parks et al., 2014). α-diversity metrics assess both the richness (number of taxa) and evenness (distribution of species abundances). We included three metrics of α diversity that each combine richness and evenness: Shannon, Simpson (this metric gives more weight to dominant species), and Fisher analyses as implemented in the Vegan package in R (Oksanen et al., 2007).

Statistical Analysis. Data were screened for outliers using the Grubb’s test (extreme studentized deviate method, http://graphpad.com/quickcalcs/grubbs1/). Group data were analyzed using one-way analysis of variance (ANOVA) with the post hoc Tukey test, and data were also analyzed using the STAMP software package (Parks et al., 2014). α-diversity metrics were calculated, and data were also analyzed using the Grubbs test implemented in the Vegan package in R (Oksanen et al., 2007).

Each OTU table was then used for further analysis to verify the clustering of microbial diversity. Permutational multivariate analysis of variance (PERMANOVA) was applied to compare the microbial communities among the groups.

Results

General Data. Data are shown in Table 1 for the four study groups: NL (n = 5), NL+FC (n = 6), CKD (n = 4), and CKD+FC (n = 6). Compared with the CKD rats consuming regular chow, the CKD rats consuming a diet supplemented with 4% ferric citrate showed a significant increase in plasma iron and blood hemoglobin concentration, a modest decline in arterial pressure and plasma creatinine concentration, and a modest rise in creatinine clearance, but no significant change in blood urea concentration. Plasma phosphorus levels were decreased as expected, as ferric citrate is a dietary phosphate binder.

Plasma levels of the gut-derived uremic toxins indoxyl sulfate and p-cresyl sulfate were increased in CKD animals compared with NL sham controls, but they were not significantly different between the CKD groups. Indoxyl sulfate was significantly decreased in CKD animals and was decreased less in the untreated CKD groups (Fisher’s α of 177 versus 174 in the NL versus NL+FC groups and 114 versus 141 in the CKD versus CKD+FC groups (P < 0.05 across groups with significant differences between NL vs. CKD and NL+FC vs. CKD). α diversity was decreased 36% in the CKD group compared with NL animals and was decreased less in the CKD+FC group (20% less diversity compared with NL). Cecal samples were not significantly different across groups (P = 0.3) although there was a similar trend for decreased diversity in the CKD groups (Fisher’s α decreased 20% and 10% in the CKD and CKD+FC groups, respectively, compared with NL animals).

Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>NL Rats</th>
<th>NL+FC</th>
<th>5/6 Nephrectomy CKD Rats</th>
<th>CKD</th>
<th>CKD+FC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>108.7 ± 3.1</td>
<td>111.7 ± 1.1</td>
<td>149.0 ± 3.4*,†</td>
<td>128.0 ± 4.8†</td>
<td></td>
</tr>
<tr>
<td>Body weight, week 6 (g)</td>
<td>408.3 ± 12.8</td>
<td>387.8 ± 8.4</td>
<td>290.0 ± 18.3*,‡</td>
<td>357.8 ± 15.5*,‡</td>
<td></td>
</tr>
<tr>
<td>Plasma phosphorus (mg/dl)</td>
<td>8.5 ± 0.2</td>
<td>8.7 ± 0.2</td>
<td>12.2 ± 0.2*,‡</td>
<td>8.7 ± 0.6†</td>
<td></td>
</tr>
<tr>
<td>Plasma calcium (mg/dl)</td>
<td>9.8 ± 0.7</td>
<td>10.4 ± 0.4</td>
<td>9.0 ± 0.5</td>
<td>9.8 ± 0.3</td>
<td></td>
</tr>
<tr>
<td>Plasma total iron (µg/dl)</td>
<td>218.4 ± 20.4</td>
<td>285.0 ± 19.1</td>
<td>167.1 ± 7.5*,‡</td>
<td>198.2 ± 21.8†</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>14.9 ± 0.1</td>
<td>14.8 ± 0.1</td>
<td>8.6 ± 0.8*,‡</td>
<td>12.4 ± 0.4*,†</td>
<td></td>
</tr>
<tr>
<td>Blood urea nitrogen (mg/dl)</td>
<td>20.1 ± 0.5</td>
<td>20.4 ± 0.3</td>
<td>160.9 ± 25.9*,‡</td>
<td>93.6 ± 26.2†</td>
<td></td>
</tr>
<tr>
<td>Plasma creatinine (mg/dl)</td>
<td>0.2 ± 0.01</td>
<td>0.2 ± 0.03</td>
<td>2.6 ± 0.2*,‡</td>
<td>1.1 ± 0.2*,‡</td>
<td></td>
</tr>
<tr>
<td>Creatinine clearance (mL/min/kg)</td>
<td>10.3 ± 2.0</td>
<td>12.1 ± 1.1</td>
<td>0.8 ± 0.1*,‡</td>
<td>2.5 ± 0.3*,†</td>
<td></td>
</tr>
</tbody>
</table>

*P < 0.05 vs. NL; †P < 0.05 vs. NL+FC; ‡P < 0.05 vs. CKD.
A Bray–Curtis distance matrix is displayed as a nonmetric multidimensional scaling (NMDS) ordination plot in Fig. 4. In these types of plots, samples with more similar microbial community composition are located closer to each other on the plot. This plot suggests that the microbial communities of individual NL rats were more similar to each other in composition than those from the CKD rats, as shown by the greater spread of the CKD-derived samples in the NMDS plot (Fig. 4).

**Ferric Citrate Treatment Affects Gut Microbial Composition in Both Normal and CKD Rats.** Ferric citrate treatment in both NL and CKD animals shifted the samples toward the origin of the vertical axis, NMDS2 (Fig. 4), so that they were clustered together more closely, with less widespread individual variability. Treatment with ferric citrate increased diversity in CKD rats, almost to the levels observed in NL rats (Fig. 3), and reduced abundances of Firmicutes in both normal and CKD rats (Fig. 1A; Supplemental Fig. 1). The Verrucomicrobia, which were largely *Akkermansia muciniphila*, had elevated abundances in the nontreated CKD rats that increased further with ferric citrate treatment in both the NL and CKD rat groups (Fig. 5). *A. muciniphila* increased from near zero to 12% of the community in the treated NL rats (Fig. 5). Similarly, other tryptophanase-possessing families, the Clostridiaceae and Enterobacteriaceae, were increased by ferric citrate treatment in both NL and CKD animals (data not shown).

A nonparametric statistical test was applied to verify the groupings that can be seen in Fig. 4. PERMANOVA is a multivariate ANOVA that tests the null hypothesis that there are no differences in microbial community composition between the health status or treatment groups, and it was applied to determine which variables explained the most
variation in microbial community composition. The control versus CKD groupings explained 9% ($P < 0.01$) of the variance in the samples (Supplemental Table 1), whereas ferric citrate treatment explained about 11% of the variance ($P < 0.01$). Samples from the colonic feces or cecum had similar composition (Fig. 1) and clustered near one another (Fig. 4), suggesting that fecal samples were largely representative of cecal samples. However, the PERMANOVA result shows that there was a significant difference between the fecal and cecal samples, with a small effect size, explaining less than 5% of the variance (Supplemental Table 1).

## Discussion

Our study supports prior reports (Aronov et al., 2011; Vaziri et al., 2013a; Wong et al., 2014) showing that the gut microbiome is markedly altered in CKD. CKD rats had lower and more variable gut microbial diversity. Both treated and untreated CKD rat microbial communities contained higher levels of Bacteroidetes and lower levels of Firmicutes, in contrast to normal animals that have more Firmicutes. Ferric citrate treatment in CKD rats increased diversity almost to the levels observed in normal animals and also brought the microbial community compositions across samples closer together. Thus, the “Anna Karenina hypothesis” may apply to the uremic microbiome, in which “all happy families look alike; each unhappy family is unhappy in its own way” (Zaneveld et al., 2017). Ferric citrate treatment also increased levels of tryptophanase-possessing families that are associated with production of indole and $p$-cresyl uremic toxins (Verrucomicrobia, Clostridiaceae, and Enterobacteriaceae); however, measured plasma levels of indoxyl sulfate and $p$-cresyl sulfate were not significantly different with ferric citrate treatment. The gut microbial changes were associated with improved kidney function (increased creatinine clearance, lower plasma creatinine) and decreased hypertension in the ferric citrate–treated CKD animals.

In an earlier study in hemodialysis patients, phylogenetic microarray analysis of microbial DNA demonstrated highly significant differences in the abundance of more than 200 bacterial OTUs belonging to 23 bacterial families compared with healthy controls (Vaziri et al., 2013a). The OTUs that were markedly increased included the Cellulomonadaceae, Clostridiaceae, Enterobacteriaceae, Moraxellaceae, Pseudomonadaceae, and Verrucomicrobiaceae families (Vaziri et al., 2013a). The Clostridiaceae, Enterobacteriaceae, and Verrucomicrobiaceae are of particular interest because these microbes

---

**Fig. 3.** $\alpha$-diversity metrics of rat fecal and cecal samples from untreated and FC-treated normal controls and CKD rats. Three $\alpha$-diversity metrics are shown: Shannon (top), Simpson (middle), and Fisher (bottom).

**Fig. 4.** An NMDS ordination plot of Bray–Curtis distances from 16S ribosomal RNA gene sequences is shown for each sample, represented by treatment group and sample type.
Fig. 5. Abundances of bacterial species amplicons that differed across the treatment groups. (A) *Akkermansia* spp. (B) *Lactobacillus* spp. Significance testing was done with the Tukey–Kramer post hoc test in STAMP software (see the Materials and Methods). Boxes indicate the inter-quartile range (IQR, 75th to 25th of the data). The median value is shown as a line within the box and the mean value as a star. Whiskers extend to the most extreme value within 1.5*IQR. Outliers are shown as crosses (+).
possess indole- and p-cresyl-forming enzymes (i.e., tryptophanase possessing families) (Wong et al., 2014) and generate gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate that translocate back into the bloodstream and contribute to systemic inflammation (Mafia et al., 2014; Rossi et al., 2014; Lau et al., 2015).

In our animal study, ferric citrate therapy increased Clostridiae, Enterobacteriaceae, and Verrucomicrobiae in the stool from CKD animals; however, plasma levels of the tryptophan-derived uremic toxins indoxyl sulfate and p-cresyl sulfate were not significantly increased. Ferric citrate therapy was associated with improved kidney function, suggesting that a potentially deleterious increase in the production of gut-derived uremic toxins was offset by improved urinary clearance. Another pathway of interest may have been the increased abundance of A. muciniphila (Verrucomicrobiae). A. muciniphila is a mucin-consuming bacterium that may have an important role in maintaining the integrity of the intestinal mucosal barrier and has anti-inflammatory properties. This species has been suggested as a biomarker of a healthy gut status (Fujio-Vejar et al., 2013) and may be induced by a low-fiber diet; however, it does not occur outside of the Western world (Desai et al., 2016; Cani and de Vos, 2017; Ottman et al., 2017; Smits et al., 2017). The increase in Akkermansia, akin to a reduction in dietary fiber, is interesting and raises further questions about whether ferric citrate influences gut mucins. Akkermansia metabolizes mucin to acetate and propionate, short-chain fatty acids that are nutrients for the host’s enterocytes (Derrien et al., 2004, 2011), and creates a positive feedback loop that stimulates mucin secretion (Derrien et al., 2010). A. muciniphila has been shown to decrease endotoxemia and regulate adipose tissue metabolism and glucose homeostasis (Everard et al., 2013; Shin et al., 2014; Anhê et al., 2015).

Patients with end-stage kidney disease show decreased numbers of gut bacteria such as Lactobacillaceae and Prevotellaceae that are able to produce the short-chain fatty acid butyrate, also an important nutrient source for host enterocytes (Vaziri et al., 2013a; Wong et al., 2014). It was recently proposed that the use of oral iron supplements might further contribute to gut microbiome alterations (Kortman et al., 2017), extrapolating from studies in African children where supplemental iron decreased the abundances of bacteria considered to be beneficial, such as Bifidobacteriaceae and Lactobacillaceae (Jaeggi et al., 2015), and increased gut permeability (Nehito et al., 2006). In an in vitro model of the human colon, where intestinal epithelial Caco-2 cells were inoculated with human microbiota, incubation with ferrous sulfate or ferric citrate altered the microbiome population and also decreased levels of Bifidobacteriaceae and Lactobacillaceae (Kortman et al., 2016). The investigators noted cytotoxicity to Caco-2 cells with effluent from iron treatment conditions that contained microbe-derived metabolites (Kortman et al., 2016). Our study confirmed a decrease in Lactobacillus counts in both normal and CKD rats treated with ferric citrate; however, this did not translate to worse kidney function or blood pressure outcomes. It should be noted that unlike the soluble ferrous sulfate and ferric citrate compounds used in the above studies, the ferric citrate employed in our study is an extremely large and insoluble complex, which is used as a phosphate binder.

Ferric citrate has other beneficial effects that may have overwhelmed any systemic impact from the altered gut microbiome. As a phosphate binder, ferric citrate ameliorates hyperphosphatemia, secondary hyperparathyroidism, and vascular calcification (Yokoyama et al., 2012, 2014; Iida et al., 2013; Block et al., 2015; Lee et al., 2015; Lewis et al., 2015). Furthermore, ferric citrate improves iron deficiency anemia (Fishbane et al., 2017), as evidenced by the increased hemoglobin levels in the treated CKD rats.

Our study is not able to define to what extent the microbiome alterations contributed to overall systemic benefits, as opposed to direct effects of ferric citrate itself. Future investigations with germ-free rodents would be one way to separate the impact of ferric citrate on the host alone, independent of the microbiota. Furthermore, there is the emerging concept of the microgenderome, whereby sex differences in the microbiome may influence systemic outcomes (Flak et al., 2013; Markle et al., 2013; Elderman et al., 2018); the current ferric citrate investigation will need to be replicated in female CKD rats to delineate sex differences in measured outcomes.

In summary, our study suggests that CKD is associated with lower and more variable gut microbial diversity. Ferric citrate therapy decreased hyperphosphatemia, improved anemia, and improved gut microbial diversity almost to the levels observed in normal animals. Lactobacillaceae were further decreased with ferric citrate therapy, whereas Verrucomicrobiae increased. Of particular interest within the Verrucomicrobiae is A. muciniphila, which has anti-inflammatory properties and promotes integrity of the intestinal barrier. The gut-derived uremic toxins indoxyl sulfate and p-cresyl sulfate were not significantly altered with ferric citrate therapy. The CKD rats treated with ferric citrate had less hypertension and better kidney function, as assessed by plasma creatinine and urinary creatinine clearance. Overall, our findings support a beneficial impact of oral ferric citrate in CKD in terms of promoting gut microbial diversity and improved kidney function.

**Authorship Contributions**

**Participated in research design:** Lau, Vaziri, Whiteson.

**Conducted experiments:** Lau, Nunes, Comeau, Langille, England, Khazaeli, Suematsu, Phan.

**Contributed new reagents or analytic tools:** Langille, Whiteson.

**Performed data analysis:** Lau, Vaziri, Nunes, England, Whiteson.

**Wrote or contributed to the writing of the manuscript:** Lau, Vaziri, Nunes, Comeau, Langille, England, Whiteson.

**References**

tion on growth, gut microbiota, metabolomics and cognitive development of rat


Ferric Citrate and the Gut Microbiome in CKD Rats


Address correspondence to: Dr. Katrine Whiteson, Department of Molecular Biology and Biochemistry, 3236 (office), 3315 (laboratory) McGaugh Hall, University of California, Irvine, CA 92697. E-mail: katrine@uci.edu; or Dr. Wei Ling Lau, Division of Nephrology and Hypertension, Department of Medicine, University of California, 333 City Blvd. West, Suite 400, Orange, CA 92868. E-mail: wllau@uci.edu
The Journal of Pharmacology and Experimental Therapeutics

Supplemental Data

Article Title: The phosphate binder ferric citrate alters the gut microbiome in rats with chronic kidney disease


Division of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, CA, USA (W.L.L., N.D.V, A.C.F.N., M.K.)
CGEB-Integrated Microbiome Resource (IMR) and Department of Pharmacology, Dalhousie University, Halifax, NS, Canada (A.M.C., M.G.I.L.)
Department of Molecular Biology & Biochemistry, University of California, Irvine, CA, USA (W.E., J.P., K.W.)
Department of Cardiology, Fukuoka University, Fukuoka, Japan (Y.S.)
Supplemental Figures

A.

![Box plot for Bacteroidetes proportion comparison.](image)

B.

![Box plot for Firmicutes proportion comparison.](image)
Supplemental Figure 1. Abundances of several bacterial taxa of interest across the four treatment groups. A) Bacteroidetes at the phyla level, B) Firmicutes at the phyla level, C) Lachnospiraceae at the family level and D) Verrucomicrobia abundance at the phyla level, largely comprised of *A. muciniphila*. CKD = chronic kidney disease animals
Supplemental Figure 2. Rarefaction curves of the 97% OTUs based on 16S rRNA gene sequences showing the number of OTUs in each sample. NL = normal controls, CKD = chronic kidney disease animals, +FC = Ferric Citrate treated.
**Supplemental Table 1.** Permanova test of the similarity of the microbial communities in the sampling groups, implemented with the Adonis test in the Vegan package in R. CKD = chronic kidney disease animals

<table>
<thead>
<tr>
<th></th>
<th>Df</th>
<th>SumsOfSqs</th>
<th>MeanSqs</th>
<th>F.Model</th>
<th>R2</th>
<th>Pr(&gt;F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD vs Normal</td>
<td>1</td>
<td>0.7748</td>
<td>0.77476</td>
<td>4.6254</td>
<td>0.08957</td>
<td>0.01**</td>
</tr>
<tr>
<td>Cecal vs fecal</td>
<td>1</td>
<td>0.3626</td>
<td>0.36256</td>
<td>2.1646</td>
<td>0.04192</td>
<td>0.04*</td>
</tr>
<tr>
<td>Ferric citrate</td>
<td></td>
<td>1</td>
<td>0.9843</td>
<td>0.98434</td>
<td>5.8767</td>
<td>0.11380</td>
</tr>
<tr>
<td>Disease and Treatment</td>
<td></td>
<td></td>
<td></td>
<td>2.9729</td>
<td>0.05757</td>
<td>0.01**</td>
</tr>
<tr>
<td>Residuals</td>
<td>36</td>
<td>6.0300</td>
<td>0.16750</td>
<td>0.69714</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>40</td>
<td>8.6496</td>
<td>1.00000</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Signif. codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1

Permanova Call:
`adonis(formula = indata_sorted ~ DiseaseState + Material + Treatment + D.T, data = inmeta_sorted, permutations = 99)`

Permutation: free
Number of permutations: 99